Nanotechnology Now - News Story: Harris & Harris: Needham Picks Up Coverage With Buy Rating

Home > News > Harris & Harris: Needham Picks Up Coverage With Buy Rating

February 22nd, 2010

Harris & Harris: Needham Picks Up Coverage With Buy Rating

Abstract:
Needham analyst Theodor Kundtz this morning picked up coverage of nanotechnology-focused investment company Harris & Harris (TINY) with a Buy rating and $8 target. The stock closed Friday at $4.59.

Source:
blogs.barrons.com

Bookmark:

Related News Press

News and information

Decoding hydrogen‑bond network of electrolyte for cryogenic durable aqueous zinc‑ion batteries January 30th, 2026

COF scaffold membrane with gate‑lane nanostructure for efficient Li+/Mg2+ separation January 30th, 2026

Breathing new life into nanotubes for a cooler planet:Researchers at Skoltech discover a simple, single-step heat treatment that nearly doubles the CO2-trapping power of carbon nanotubes January 30th, 2026

New light-based nanotechnology could enable more precise, less harmful cancer treatment: The approach offers a potential alternative to chemotherapy and radiation by using light and heat to target cancer cells. January 30th, 2026

Investments/IPO's/Splits

Daikin Industries becomes OCSiAl shareholder July 27th, 2021

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

Announcements

Decoding hydrogen‑bond network of electrolyte for cryogenic durable aqueous zinc‑ion batteries January 30th, 2026

COF scaffold membrane with gate‑lane nanostructure for efficient Li+/Mg2+ separation January 30th, 2026

Financial Reports

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021



Premium Products


	Only the news you want to read! Learn More



	Full-service, expert consulting Learn More




	The latest news from around the world, FREE